Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients

Antiviral Therapy

Volumn 22, Issue 6, 2017, Pages 481-493

  Backus, Lisa I ^a   Belperio, Pamela S ^a   Shahoumian, Troy A ^a   Loomis, Timothy P ^a   Mole, Larry A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; PROTON PUMP INHIBITOR; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN CELL; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL HEALTH; MIDDLE AGED; NONHUMAN; OBSERVATIONAL STUDY; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RACE DIFFERENCE; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTE COUNT; TREATMENT DURATION; COMBINATION DRUG THERAPY; COMORBIDITY; GENETICS; GENOTYPE; HEPACIVIRUS; ORAL DRUG ADMINISTRATION; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85037046006     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3117     Document Type: Article

References (24)

1. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889–1898.
2. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483–1493.
3. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983–1992.
4. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973–1982.
5. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive Cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163:1–13.
6. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433–1444.
7. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705–714.
8. Backus LI, Belperio PS, Loomis TP, et al. Hepatitis C virus screening and prevalence among US veterans in Department of Veterans Affairs care. JAMA Intern Med 2013; 173:1549–1552.
9. Backus LI, Gavrilov S, Loomis TP, et al. Clinical case registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009; 16:775–783.
10. Backus LI, Belperio PS, Shahoumian TA, et al. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther 2016; 44:400–410.
11. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013; 158:807–820.
12. Thornton K, Deming P, Manch RA, et al. Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment. Hepatol Int 2016; 10:624–631.
13. Maasoumy B, Vermehren J, Welker MW, et al. Clinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimens. J Hepatol 2016; 65:473–482.
14. Kowdley KV, Nelson DR, Lalezari JP, et al. On-treatment HCV RNA as a predictor of sustained virologic response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir. Liver Int 2016; 36:1611–1618.
15. Sidharthan S, Kohli A, Sims Z, et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis 2015; 60:1743–1751.
16. Pillai AA, Wedd J, Norvell JP, et al. Simeprevir and sofosbuvir (SMV-SOF) for 12 weeks for the treatment of chronic hepatitis C genotype 1 infection: a real world (transplant) hepatology practice experience. Am J Gastroenterol 2016; 111:250–260.
17. Welzel TM, Herrmann E, Marcellin P, et al. On treatment HCV RNA as a predictor of virologic response in the ledipasvir/sofosbuvir Phase 3 program for HCV genotype 1 infection: analysis of the ION-1, ION-2, and ION-3 studies. Hepatology 2014; 60:1132A.
18. Aqel BA, Pungpapong S, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 2015; 62:1004–1012.
19. Tapper EB, Bacon BR, Curry MP, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology 2016; 64:1893–1899.
20. Dietz J, Rupp D, Susser S, et al. Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy. PLoS One 2016; 11:e0156731.
21. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2016; 64:486–504.
22. Alsio Å, Rembeck R, Askarieh G, et al. Impact of obesity on the bioavailability of peginterferon-a2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. PLoS One 2012; 7:e37521.
23. Hickman IJ, Clouston AD, MacDonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51:89–94.
24. Gowda C, Brown TT, Compher C, et al. Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection. AIDS 2016; 30:2519–2528.